<DOC>
	<DOCNO>NCT01577381</DOCNO>
	<brief_summary>The purpose study determine efficacy , safety tolerability multiple dos RN6G subject Geographic Atrophy Secondary Age-related Macular Degeneration .</brief_summary>
	<brief_title>Efficacy , Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary Age-related Macular Degeneration</brief_title>
	<detailed_description>The trial terminate early April 12 , 2013 due organizational decision , base safety efficacy concern . Subjects already enrol study follow .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Men woman age 60 90 year . Diagnosis geographic atrophy ( GA ) secondary dry AgeRelated Macular Degeneration . Best Corrected Visual Acuity ( BCVA ) 20/80 good study eye Evidence ocular disease geographic atrophy ( GA ) secondary dry AgeRelated Macular Degeneration study eye . History diagnosis exudative ( wet ) AgeRelated Macular Degeneration , subretinal choroidal neovascular lesion study eye . Presence disease condition might compromise cardiovascular , hematological , renal , hepatic , pulmonary , endocrine , central nervous , immune , gastrointestinal system</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>Advanced Dry Age-Related Macular Degeneration</keyword>
	<keyword>Geographic Atrophy</keyword>
	<keyword>RN6G</keyword>
</DOC>